

BLAU FARMACÊUTICA S.A.

Publicly-held company NIRE 35.300.416.406 CVM Code No. 2462-7

NOTICE TO THE MARKET

Sale of Botulinum Toxin Registry

A **BLAU FARMACÊUTICA S.A**. (Ticker: BLAU3; "Blau" or "Company"), a publicly-held company operating in the biotechnology sector, hereby informs its shareholders and the market in general, following the <u>Notice to the Market of 03/25/2024</u>, which concluded the sale of one of its botulinum toxin registrations, for the amount of USD 7.5 million, 90% of which is already in the Company's cash and the remaining 10% will be received by 05/12/2025.

Blau maintains the rights to the Botulim brand and the operation with two brands, as it also owns the Botulift brand, which was acquired in June 2023, comprising the Laboratório Bergamo portfolio.

Blau continues to be the market leader in the product, considering the sum of the two brands, and reinforces its intention to expand the portfolio of its Aesthetics Business Unit with new products in Brazil and other Latin American countries where we operate.

Cotia, March 20, 2025.

Douglas Leandro Rodrigues

Chief Financial and Investor Relations Officer

About Blau Farmacêutica: Blau is a leading pharmaceutical company in the institutional segment and a pioneer in biotechnology, with a portfolio of private brands of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, operating in several therapeutic classes. Blau has a continental presence, currently in 7 Latin American countries – Brazil, Argentina, Colombia, Chile, Ecuador, Peru, Uruguay and the United States, and has a modern pharmaceutical industrial complex, consisting of five industrial plants, with state-of-the-art technology, dedicated to the production of biological, oncological, antibiotic, injectable anesthetics and biotechnological drugs.